Thyrocare Technologies Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 12.1 pts more than Nifty Microcap 250 and 11.0 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies reported strong Q1 FY26 results with consolidated revenue from operations rising to Rs. 193.03 crores, up about 23% from Rs. 156.91 crores in the same quarter last year. Consolidated profit after tax jumped roughly 60% YoY to Rs. 38.29 crores (vs Rs. 23.94 crores), with basic EPS climbing to Rs. 7.35 from Rs. 4.52. Standalone numbers also showed healthy growth, with revenue up around 24.5% to Rs. 178.89 crores and PAT of Rs. 36.05 crores. The Diagnostic Testing segment remained the main growth driver, contributing Rs. 178.33 crores in revenue and Rs. 44.85 crores in segment profit. Auditors MSKA & Associates issued an unmodified (clean) review report on both standalone and consolidated results.
Strong double-digit revenue and even stronger profit growth signal solid operating momentum, which is positive for shareholders. The CFO transition is a routine internal move linked to the parent API Holdings, with no negative signal, though investors may watch for any disruption during the handover.